Moreover, this immune-related tumor-inhibitory phenotype is specific to BCL-XL degradation, given that inhibition of BCL-2 with BCL-2-specific inhibitor ABT-199 (ref. 10), which did not cause an increase in the activation of TI-CD8+ T cells (Supplementary Fig. 7l), did not inhibit the growth of MC38 or Renca tumors, even with daily administration of much higher doses than DT2216 (Supplementary Fig. 7m, n). Here, BCL2 is linked to neoplasm.